Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting
Authors:
- Kok-Yuen HoKHKok-Yuen Ho
- Tong J GanTGTong J Gan
- 1 December 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 19 (6) , 606-611
Abstract
The use of selective 5-hydroxytryptamine type 3 receptor antagonists has improved the management of postoperative nausea and vomiting, but has not completely eliminated it. In this article, we discuss the pharmacology of 5-hydroxytryptamine type 3 receptor antagonists and the impact of pharmacogenetics on postoperative nausea and vomiting. Dolasetron, granisetron, ondansetron, palonosetron, and tropisetron have similar mechanisms of action but different pharmacokinetic and pharmacodynamic properties. Genetic polymorphism in the cytochrome P450 mono-oxygenase system, drug efflux transporter adenosine triphosphate-binding cassette subfamily B member 1 and 5-hydroxytryptamine type 3 receptor subunits also contribute to the interindividual variation in response to different 5-hydroxytryptamine type 3 receptor antagonists. These differences account for differences in the duration of action and clinical efficacy of these agents. Pharmacogenetics testing in patients may help differentiate responders to 5-hydroxytryptamine type 3 receptor antagonists from non-responders and allow the anesthesiologist to individualize antiemetic therapy. The cost-effectiveness of such screening in postoperative nausea and vomiting management has, however, not been evaluated. Given the multifactorial nature of postoperative nausea and vomiting, a multimodal approach to reduce or eliminate risk factors will be most successful in its management.Keywords
This publication has 42 references indexed in Scilit:
- 5-HT3-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer TreatmentOncology, 2005
- Selective Serotonin 5-HT 3 Receptor Antagonists for Postoperative Nausea and VomitingCNS Drugs, 2005
- Granisetron: An Update on its Clinical Use in the Management of Nausea and VomitingThe Oncologist, 2004
- PalonosetronDrugs, 2004
- Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers2001
- 5-HT3 receptor antagonistsvs traditional agents for the prophylaxis of postoperative nausea and vomitingCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2000
- PharmacogeneticsBritish Medical Bulletin, 1999
- 5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and VomitingDrugs, 1998
- Biotransformation of the antiemetic 5-HT3 antagonist tropisetron in liver and kidney slices of human, rat and dog with a comparison to in vivoEuropean Journal of Drug Metabolism and Pharmacokinetics, 1996
- Postoperative Nausea and VomitingAnesthesiology, 1992